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Unavailability of adequate methods of viral attenuation in the early 
1980’s led to the transfusion of human blood-derived components 
from donors infected with Hepatitis C virus (HCV).1, 2, 3 
 
Patients with hereditary bleeding disorders (HBDs) treated with human 
blood-derived components were infected with HCV, around 20% 
naturally eradicated their HCV infection. 4 
 
Approximately 80% developed chronic HCV. 10-20% progressed to    
end –stage liver disease in more than two decades.4 
 
One of the major difficulties in monitoring HCV infection is that liver 
biochemistry and clinical status do not reflect the histology or disease 
activity.5 
Introduction 
Analysis of a series of 161 patients with HBDs treated in the 
Haemophilia Center of the Immunohaemotherapy Department of the 
Centro Hospitalar de Lisboa Central (Lisboa, Portugal). 
 
Systematic review of the patients’ clinical data. Collection of the HCV 
serum markers’ evolution for each patient. 
 
Elaboration of a Microsoft® Office Access database comprising the 
information gathered and statistical study, using Microsoft® Office 
Excel, of its variables: age, gender, degree of severity of the bleeding 
disorder, treatment frequency and modality and HCV infection serum 
markers. 
Methods 
More than 80% (n=130) of the patients with HBDs followed in our Center have been studied for HCV infection. 40% (n=65) are infected. 
 
Considering that most patients were infected in the late 70s and early 80s and the natural evolution of HCV infection in patients without HBDs, it is expected that 
the prevalence of major complications will rise significantly in the coming years. 
 
In order to be properly attended to, these patients should be identified as forming a subpopulation among the population of patients treated in our Center for 
HBDs, which is particularly vulnerable if not monitored adequately. 
 
Therefore, this subpopulation requires our utmost attention and careful planning in order to achieve optimum prophylactic management and follow up of the 
disease and its potentially serious complications. 
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PO-MO-099 – INFECTIOUS COMPLICATIONS 
  Haemophilia A 
(n=112) 
Haemophilia B 
(n=23) 
von Willebrand’s Disease 
(n=26) 
  Severe Moderate Mild Severe Moderate or Mild Type 2 Type 3 
Number of patients 
(n=161) 
58 14 40 13 10 19 7 
36% 9% 25% 8% 6% 12% 4% 
Age (years) 
41,0 35,6 42,3 36,1 53,6 53,0 43,0 
± 14,4 ± 10,0 ± 15,2 ± 13,6 ± 15,3 ± 17,7 ± 10,7 
Gender 
Male 100% 100% 100% 100% 100% 21% 29% 
Female - - - - - 79% 71% 
Treatment 
frequency 
On demand 38 14 40 10 10 - - 
Prophylactic 20 - - 3 - - - 
Treatment 
modality 
Human blood-derived 34 5 6 11 4 - - 
Recombinant 24 9 34 2 6 - - 
HCV 
infected 
Positive 
36 8 8 3 1 3 6 
62% 57% 20% 23% 10% 16% 86% 
Negative 
17 4 25 8 6 5 
- 
29% 29% 63% 62% 60% 26% 
Not available 
5 2 7 2 3 11 1 
9% 14% 17% 15% 30% 58% 14% 
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To define and characterize the subpopulation of HCV infected patients 
among the population of patients with HBDs followed in our Center. 
 
To study and determine the number, age, gender and treatment 
modality of HCV infected patients in the subpopulation. 
Objectives 
